Wendy Parulekar
Senior investigator behind CCTG's breast cancer trials, including the MA.17 and MA.32 studies of extended endocrine therapy and metformin.
Wendy Parulekar has led or co-led Canadian Cancer Trials Group breast cancer studies including MA.17R (extended letrozole) and MA.32 (metformin), and oversees the group's trial operations.
| Title | Journal | Year |
|---|---|---|
| Extending aromatase-inhibitor adjuvant therapy to 10 years (MA.17R) | NEJM | 2016 |
Pages like this
not linked directly; found by shared links- TrialPALOMA-2
Shares Letrozole (and other aromatase inhibitors), HR-positive / HER2-negative breast cancer.
- TrialMONALEESA-2
Shares Letrozole (and other aromatase inhibitors), HR-positive / HER2-negative breast cancer.
- PersonAnn H. Partridge
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- IdeaRotate between drugs on a fixed schedule instead of waiting for failure
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- TermAromatase inhibitor
Shares Letrozole (and other aromatase inhibitors), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- IdeaHormone tablets instead of surgery for small breast cancers in the frail over-80s
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- TrialMONARCH 3
Shares Letrozole (and other aromatase inhibitors), HR-positive / HER2-negative breast cancer.
- InstitutionCancer Care Alberta (Alberta Health Services)
Shares Canadian Cancer Trials Group (CCTG), HR-positive / HER2-negative breast cancer.